Ingestion of Simethicone After Capsule Ingestion and Its Impact on Quality of Video Capsule Endoscopy- a Pilot Study

Sponsor
Albany Medical College (Other)
Overall Status
Unknown status
CT.gov ID
NCT03166605
Collaborator
(none)
36
1
3
24.9
1.4

Study Details

Study Description

Brief Summary

Wireless video capsule endoscopy (VCE) is a non-invasive technology that looks into small intestine and gives images of its lumen as the wireless capsule passes through it. It is used widely to access this anatomically difficult part of the body that cannot be seen via either colonoscopy or endoscopy. Currently various studies have been done that give multiple comparisons between various bowel preparation in terms of quality of the small bowel visualization. No studies have been done where simethicone (Gas-X) is ingested after capsule swallowing. We intend to give patients simethicone 1 hour after capsule ingestion for two consecutive hours and compare results of capsule endoscopy outcomes like small bowel transit time (SBTT), diagnostic yield (DY), small bowel visualization quality (SBVQ) and completion rate (CR).

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Currently various studies have been done that give multiple comparisons between various bowel preparation in terms of small bowel transit time (SBTT), diagnostic yield (DY), small bowel visualization quality (SBVQ), completion rate (CR). Studies suggest that using Polyethylene glycol (PEG) prep is significantly better compared to clear liquid and overnight fast in terms if SBVQ and DY (Rokkas et al 2009). Other studies have shown using simethicone 30 minutes before capsule ingestion increases visibility compared to clear liquid and PEG preparation but no significant difference in gastrointestinal transit time or examination completion rate (Wei et al 2008). No studies have been done where simethicone is ingested after capsule swallowing.

Simethicone helps absorb the air bubble in the lumen which can improve the image quality. It decreases the surface tension of gas bubbles thereby dissolving them and preventing gas pockets from forming in GI system. It's often used over the counter for gas relief. Gastric emptying time is usually less than 5 hours, small bowel transit time is usually less than 6 hours, and colonic transit time is usually less than 59 hours (Rao et al 2009). Giving simethicone till 2 hours after swallowing capsule can help clear gas bubble before the capsule migrates into the small bowel.

Albert et al 2004 gave patients 80mg simethicone before swallowing the wireless capsule for their study. Wei et al 2008 gave 300mg of simethicone 20 minutes before swallowing the capsule. Chen et al 2011 gave 20ml (40mg/ml) simethicone 30 minutes before capsule ingestion which amounts to 800 mg total. Current FDA recommendation for adults is 500mg maximum daily dose. The liquid form comes in concentration of 20mg/0.3ml which constitutes to 7.5 ml for 500mg dose.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Control, Sham , ExperimentalControl, Sham , Experimental
Masking:
Double (Care Provider, Outcomes Assessor)
Masking Description:
Randomized control
Primary Purpose:
Diagnostic
Official Title:
Ingestion of Simethicone After Capsule Ingestion and Its Impact on Quality of Video Capsule Endoscopy- a Pilot Study
Actual Study Start Date :
May 3, 2017
Anticipated Primary Completion Date :
Mar 1, 2019
Anticipated Study Completion Date :
Jun 1, 2019

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

First group: Control Follow the current standard protocol used at Albany Medical Center that includes: Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast. Return to clinic (RTC) 8 hours after to remove equipment Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period

Sham Comparator: Sham

Receive 3 ml simethicone 20 minutes prior to capsule swallowing Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast. Return to clinic (RTC) 8 hours after to remove equipment Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period.

Drug: Simethicone
Giving simethicone before and after capsule ingestion.

Experimental: Experiment

Receive 3 ml simethicone 20 minutes prior to capsule swallowing. Receive 3 ml simethicone 1 hours after capsule swallowing Receive 1.5 ml simethicone 2 hours after capsule swallowing Do not drink anything for an additional 1 hour after taking last simethicone dose. After which patient may drink clear liquids Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast. Return to clinic (RTC) 8 hours after to remove equipment Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period.

Drug: Simethicone
Giving simethicone before and after capsule ingestion.

Outcome Measures

Primary Outcome Measures

  1. Small bowel visualization quality (SBVQ) [8 hours]

Secondary Outcome Measures

  1. Small bowel transit time (SBTT), [8 hours]

  2. Diagnostic yield (DY) [8 hours]

  3. completion rate (CR) [8 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients aged 18 and older

  • patients undergoing capsule endoscopy for standard of care

  • patients able to give consent for themselves

Exclusion Criteria:

• prisoners

Contacts and Locations

Locations

Site City State Country Postal Code
1 Albany medical center Albany New York United States 12208

Sponsors and Collaborators

  • Albany Medical College

Investigators

  • Principal Investigator: Asra Batool, MD, Albany Medical College
  • Principal Investigator: Gurjiwan s Virk, MD, Albany Medical College

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gurjiwan Virk, MD, Resident Physician, Albany Medical College
ClinicalTrials.gov Identifier:
NCT03166605
Other Study ID Numbers:
  • 4849
First Posted:
May 25, 2017
Last Update Posted:
Jun 26, 2018
Last Verified:
Jun 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 26, 2018